$12.17
+0.87 (+7.70%)
Last updated: Apr 16, 2026 01:08
Fundamentals Overview
NovoCure Limited is near the low of its 52-week range with moderate valuation, showing strong upward momentum today.
Valuation moderate
Risk (Beta)
0.82 — in line vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Sentiment improving (2 upgrades)
Pressures (Sell):
Analyst grade: D+ · 3M vs S&P 500: -14.9% · 3M vs Healthcare sector: -8.1%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 10, Equal Weight: 1, In Line: 2, Neutral: 10, Outperform: 1, Overweight: 6.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-34.46; current price is $12.17. That’s a -383.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 3.98 |
| P/S (TTM) | 2.11 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.9 |
| Quick Ratio (TTM) | 2.9 |
| Cash Ratio (TTM) | 0.46 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -20.79% |
| Gross margin (TTM) | 74.54% |
| Operating margin (TTM) | -23.47% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for NVCR.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-26 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-12 |
| Wedbush | maintain | Neutral | Neutral | 2026-01-15 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-01-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-30 |
| JP Morgan | maintain | Neutral | Neutral | 2025-10-27 |
| Wells Fargo | downgrade | Overweight | Equal Weight | 2025-07-25 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-06-27 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-04-23 |
| Wedbush | maintain | Neutral | Neutral | 2025-04-16 |
| JP Morgan | maintain | Neutral | Neutral | 2025-04-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-01-14 |
| Piper Sandler | maintain | Overweight | Overweight | 2024-12-13 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-03 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-12-02 |
| Evercore ISI Group | upgrade | In Line | Outperform | 2024-12-02 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-11-21 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-10-31 |
| HC Wainwright & Co. | upgrade | Neutral | Buy | 2024-10-16 |
| Evercore ISI Group | maintain | In Line | In Line | 2024-10-01 |
| Wells Fargo | maintain | Overweight | Overweight | 2024-07-26 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-07-26 |
| Evercore ISI Group | maintain | In Line | In Line | 2024-07-02 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-06-04 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-05-02 |
| Piper Sandler | maintain | Overweight | Overweight | 2024-04-10 |
| Wells Fargo | maintain | Overweight | Overweight | 2024-04-03 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-03-27 |
| JP Morgan | maintain | Neutral | Neutral | 2024-03-19 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-03-12 |